logo

BCDA

Biocardia·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

BCDA fundamentals

Biocardia (BCDA) released its earnings on Nov 12, 2025: revenue was 0 (YoY -100.00%), beat estimates; EPS was -0.24 (YoY +60.66%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.24
+60.66%
Report date
Nov 12, 2025
BCDA Earnings Call Summary for Q3,2025
  • Clinical Milestones: CardiAmp HF II trial enrolling at four centers; Japan PMDA consultations and FDA meeting in Q4 2025. BCDA02 CMI data shows 80-second exercise improvement in five patients.
  • Financial Stability: $5.3 million cash runway to Q2 2026; no immediate funding needs. R&D expenses up 0.5% YoY due to trial expansion.
  • Regulatory Focus: Helix system FDA submission Q4 2025; potential Japan approvals for CardiAmp HF and allogeneic stem cells.
  • Partnerships & Innovation: Heart 3D fusion imaging with CARTech for enhanced delivery; NIH funding for BCDA03 trial.
EPS
Revenue

Revenue & Expenses

Key Indicators

Biocardia (BCDA) key financial stats and ratios, covering profitability, financial health, and leverage.
Biocardia (BCDA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Biocardia (BCDA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Biocardia (BCDA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Biocardia (BCDA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Biocardia (BCDA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield